Aldeyra Therapeutics, Inc. (ALDX): Price and Financial Metrics


Aldeyra Therapeutics, Inc. (ALDX): $6.09

0.01 (+0.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALDX to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALDX Stock Price Chart Interactive Chart >

Price chart for ALDX

ALDX Price/Volume Stats

Current price $6.09 52-week high $7.99
Prev. close $6.08 52-week low $2.36
Day low $5.93 Volume 363,601
Day high $6.26 Avg. volume 348,172
50-day MA $6.17 Dividend yield N/A
200-day MA $5.20 Market Cap 356.63M

Aldeyra Therapeutics, Inc. (ALDX) Company Bio


Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.


ALDX Latest News Stream


Event/Time News Detail
Loading, please wait...

ALDX Latest Social Stream


Loading social stream, please wait...

View Full ALDX Social Stream

Latest ALDX News From Around the Web

Below are the latest news stories about ALDEYRA THERAPEUTICS INC that investors may wish to consider to help them evaluate ALDX as an investment opportunity.

Insiders made the right call by buying US$1.2m Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) stock this year, currently sit on US$349k profit

Insiders who bought Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) in the last 12 months may probably not pay attention to...

Yahoo | January 12, 2023

Aldeyra Therapeutics Submits New Drug Application to the U.S. Food and Drug Administration for ADX‑2191 for the Treatment of Primary Vitreoretinal Lymphoma

LEXINGTON, Mass., December 21, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADX‑2191 (methotrexate injection, USP), an investigational drug candidate, for the treatment of primary vitreoretinal lymphoma, a rare but potentially fatal cancer with no FDA-approved therapy.

Yahoo | December 21, 2022

Aldeyra Therapeutics' RASP Modulator Shows Improved Signs of Alcohol Intoxication

Aldeyra Therapeutics Inc (NASDAQ: ALDX) announced a demonstration of target engagement and improvement in the signs of alcohol intoxication in the Phase 2 trial of ADX-629. Relative to the placebo, ADX-629 reduced dermal flushing, increased Romberg test balance time, and lowered ethanol RASP metabolite acetaldehyde levels following acute alcohol exposure. ADX-629 and placebo were well tolerated, and no safety concerns were noted. Related: Aldeyra's ADX-2191 Aces Late-Stage Study In Rare Vision D

Yahoo | December 13, 2022

Aldeyra Therapeutics’ Investigational RASP Modulator ADX-629 Improved Signs of Intoxication in Alcohol Challenge Phase 2 Clinical Trial

LEXINGTON, Mass., December 13, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced demonstration of target engagement and improvement in the signs of alcohol intoxication in a sequence-randomized, double-masked, placebo-controlled crossover Phase 2 clinical trial of ADX-629, a first-in-class orally administered investigational new drug candidate. Relative to placebo, ADX-629 reduced dermal flushing (P=0.0007), increased Romberg test balance time (P=0.02), and lowered levels

Yahoo | December 13, 2022

Aldeyra Therapeutics Announces Positive Primary Vitreoretinal Lymphoma Pre-NDA Meeting with the FDA

LEXINGTON, Mass., December 01, 2022--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that, following the recent receipt of official minutes from its pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration (FDA), the Company plans to submit an NDA as soon as the end of 2022 for marketing approval of the investigational drug candidate ADX-2191 for the treatment of primary vitreoretinal lymphoma.

Yahoo | December 1, 2022

Read More 'ALDX' Stories Here

ALDX Price Returns

1-mo -8.01%
3-mo 8.75%
6-mo 20.83%
1-year 86.81%
3-year 5.18%
5-year -18.26%
YTD -12.50%
2022 74.00%
2021 -41.69%
2020 18.07%
2019 -30.00%
2018 22.06%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.6587 seconds.